Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Sangamo Therapeutics Inc (NASDAQ: SGMO) closed at $0.58 in the last session, down -3.29% from day before closing price of $0.6. In other words, the price has decreased by -$3.29 from its previous closing price. On the day, 4.34 million shares were traded. SGMO stock price reached its highest trading level at $0.6055 during the session, while it also had its lowest trading level at $0.5675.
Ratios:
We take a closer look at SGMO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.05 and its Current Ratio is at 1.05. In the meantime, Its Debt-to-Equity ratio is 1.20 whereas as Long-Term Debt/Eq ratio is at 1.20.
On December 10, 2024, H.C. Wainwright reiterated its Buy ratingand also kept the price unchanged to $10.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 03, 2023, whereas the target price for the stock was revised from $6 to $2.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 174478592 and an Enterprise Value of 159595600. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.14 while its Price-to-Book (P/B) ratio in mrq is 8.05. Its current Enterprise Value per Revenue stands at 1.953 whereas that against EBITDA is -2.739.
Stock Price History:
The Beta on a monthly basis for SGMO is 1.26, which has changed by -0.7222222 over the last 52 weeks, in comparison to a change of 0.18286073 over the same period for the S&P500. Over the past 52 weeks, SGMO has reached a high of $3.18, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is -3.94%, while the 200-Day Moving Average is calculated to be -16.61%.
Shares Statistics:
According to the various share statistics, SGMO traded on average about 5.25M shares per day over the past 3-months and 4248530 shares per day over the past 10 days. A total of 301.71M shares are outstanding, with a floating share count of 291.43M. Insiders hold about 3.41% of the company’s shares, while institutions hold 17.28% stake in the company. Shares short for SGMO as of 1760486400 were 17116249 with a Short Ratio of 3.26, compared to 1757894400 on 17678359. Therefore, it implies a Short% of Shares Outstanding of 17116249 and a Short% of Float of 5.72.
Earnings Estimates
As of right now, 3 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.07 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.37 and -$0.43 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.3, with 3.0 analysts recommending between -$0.12 and -$0.4.
Revenue Estimates
According to 5 analysts,. The current quarter’s revenue is expected to be $34.4M. It ranges from a high estimate of $100M to a low estimate of $4M. As of. The current estimate, Sangamo Therapeutics Inc’s year-ago sales were $49.41M
A total of 5 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $124.7M, while the lowest revenue estimate was $34.7M, resulting in an average revenue estimate of $72.3M. In the same quarter a year ago, actual revenue was $57.8MBased on 5 analysts’ estimates, the company’s revenue will be $48.3M in the next fiscal year. The high estimate is $114.2M and the low estimate is $8.6M.
